265 related articles for article (PubMed ID: 1372861)
1. Intravenous immune globulins. A review of their uses in selected immunodeficiency and autoimmune diseases.
Pirofsky B; Kinzey DM
Drugs; 1992 Jan; 43(1):6-14. PubMed ID: 1372861
[TBL] [Abstract][Full Text] [Related]
2. Use of intravenous immune globulin therapy: an overview.
Wordell CJ
DICP; 1991; 25(7-8):805-17. PubMed ID: 1949941
[TBL] [Abstract][Full Text] [Related]
3. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology.
Orange JS; Hossny EM; Weiler CR; Ballow M; Berger M; Bonilla FA; Buckley R; Chinen J; El-Gamal Y; Mazer BD; Nelson RP; Patel DD; Secord E; Sorensen RU; Wasserman RL; Cunningham-Rundles C;
J Allergy Clin Immunol; 2006 Apr; 117(4 Suppl):S525-53. PubMed ID: 16580469
[TBL] [Abstract][Full Text] [Related]
4. Safety of IGIV therapy and infusion-related adverse events.
Ballow M
Immunol Res; 2007; 38(1-3):122-32. PubMed ID: 17917017
[TBL] [Abstract][Full Text] [Related]
5. [New indications for gamma globulins].
Fontán G; García MC; Pascual-Salcedo D; López Trascasa M; Alvarez Doforno R; Ferreira A
An Esp Pediatr; 1992 Jun; 36 Suppl 48():135-8. PubMed ID: 1379010
[TBL] [Abstract][Full Text] [Related]
6. [Immunoglobulins--merely expensive or also useful?].
Paar WD
Ther Umsch; 1995 Oct; 52(10):639-44. PubMed ID: 7482374
[TBL] [Abstract][Full Text] [Related]
7. [Intravenous immunoglobulins in hematologic therapy].
Giovanelli E
Clin Ter; 1992 Sep; 141(9 Pt 2):69-73. PubMed ID: 1468201
[TBL] [Abstract][Full Text] [Related]
8. Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases.
Daoud YJ; Amin KG
Int Immunopharmacol; 2006 Apr; 6(4):600-6. PubMed ID: 16504922
[TBL] [Abstract][Full Text] [Related]
9. Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms.
Bayry J; Dasgupta S; Misra N; Ephrem A; Duong Van Huyen JP; Delignat S; Hassan G; Caligiuri G; Nicoletti A; Lacroix-Desmazes S; Kazatchkine MD; Kaveri S
Int Immunopharmacol; 2006 Apr; 6(4):528-34. PubMed ID: 16504915
[TBL] [Abstract][Full Text] [Related]
10. You can make a difference in the administration of intravenous immunoglobulin therapy.
Duff K
J Infus Nurs; 2006; 29(3 Suppl):S5-14. PubMed ID: 16878850
[TBL] [Abstract][Full Text] [Related]
11. [Intravenous immunoglobulin therapy].
Mouthon L
Rev Prat; 2005 May; 55(10):1049-56. PubMed ID: 16097244
[TBL] [Abstract][Full Text] [Related]
12. Immunoregulation of autoimmune disorders: the role of intravenous immunoglobulins.
Luzi G; Ferrara R
Int J Artif Organs; 1993 Dec; 16 Suppl 5():189-95. PubMed ID: 8013987
[TBL] [Abstract][Full Text] [Related]
13. Update on the use of immunoglobulin in human disease: A review of evidence.
Perez EE; Orange JS; Bonilla F; Chinen J; Chinn IK; Dorsey M; El-Gamal Y; Harville TO; Hossny E; Mazer B; Nelson R; Secord E; Jordan SC; Stiehm ER; Vo AA; Ballow M
J Allergy Clin Immunol; 2017 Mar; 139(3S):S1-S46. PubMed ID: 28041678
[TBL] [Abstract][Full Text] [Related]
14. The patient: Emerging clinical applications of intravenous immunoglobulin.
Harvey RD
Pharmacotherapy; 2005 Nov; 25(11 Pt 2):85S-93S. PubMed ID: 16229679
[TBL] [Abstract][Full Text] [Related]
15. Clinical and investigational considerations for the use of IGIV therapy.
Ballow M
Am J Health Syst Pharm; 2005 Aug; 62(16 Suppl 3):S12-8; quiz S19-21. PubMed ID: 16100383
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial.
Roifman CM; Schroeder H; Berger M; Sorensen R; Ballow M; Buckley RH; Gewurz A; Korenblat P; Sussman G; Lemm G
Int Immunopharmacol; 2003 Sep; 3(9):1325-33. PubMed ID: 12890430
[TBL] [Abstract][Full Text] [Related]
17. Availability of immune globulin intravenous for treatment of immune deficient patients--United States, 1997-1998.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1999 Mar; 48(8):159-62. PubMed ID: 10079062
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease.
Heimall J; Chen J; Church JA; Griffin R; Melamed I; Kleiner GI
J Clin Immunol; 2016 Aug; 36(6):600-9. PubMed ID: 27342758
[TBL] [Abstract][Full Text] [Related]
19. Systemic and topical immunoglobulin treatment in immunocompromised patients.
Hammarström L; Gardulf A; Hammarström V; Janson A; Lindberg K; Smith CI
Immunol Rev; 1994 Jun; 139():43-70. PubMed ID: 7523279
[No Abstract] [Full Text] [Related]
20. Impact of Site of Care on Infection Rates Among Patients with Primary Immunodeficiency Diseases Receiving Intravenous Immunoglobulin Therapy.
Wasserman RL; Ito D; Xiong Y; Ye X; Bonnet P; Li-McLeod J
J Clin Immunol; 2017 Feb; 37(2):180-186. PubMed ID: 28160239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
